Lenvatinib Efficacy in Metastatic Neuroendocrine Tumors
NCT ID: NCT02678780
Last Updated: 2025-07-24
Study Results
Results available
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE2
Total Enrollment
123 participants
Study Classification
INTERVENTIONAL
Study Start Date
2015-10-31
Study Completion Date
2020-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This is a prospective, international, multi-center, open label, stratified, exploratory phase II study evaluating the efficacy and safety of lenvatinib in patients with advanced/metastatic, neuroendocrine tumors of the pancreas after progression to a previous targeted agent (cohort A) or gastrointestinal tract after progression to somatostatin analogues (cohort B).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung
NCT01877083
KIF5B-RET-Positive Adenocarcinoma of the Lung
COMPLETED
PHASE2
Phase II Clinical Study of Leflunomide in the Treatment of MEN-1 Neuroendocrine Tumor
NCT06540937
Neuroendocrine Tumors
RECRUITING
PHASE2
DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.
NCT05770544
Haematological Malignancy
Malignancy
Malignant Neoplasm
+8 more
RECRUITING
PHASE2/PHASE3
A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer
NCT05297890
Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
ACTIVE_NOT_RECRUITING
PHASE2
Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR Mutations
NCT05258279
Non-squamous Non-small-cell Lung Cancer
EGFR Activating Mutation
ACTIVE_NOT_RECRUITING
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Trial to assess the efficacy of Lenvatinib in metastatic neuroendocrine tumor. The primary endpoint of the study is overall response rate (ORR) by RECIST v 1.1 upon central radiologic assessment.
Number of patients: 110 patients Estimated duration of subject participation: 24 months
Number of patients: 110 patients Estimated duration of subject participation: 24 months
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Neuroendocrine Tumors
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NON_RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort A
Patients with advanced/metastatic, histologically confirmed, grade 1/2 (G1/G2) of 2010 WHO (World Health Organization) classification neuroendocrine tumors of the pancreas after progression to a previous targeted agent.
Treatment: Dosing schedule of 24 mg once a day of Lenvatinib (two 10-mg capsules + one 4-mg capsule)
Group Type
EXPERIMENTAL
Lenvatinib
Intervention Type
DRUG
Cohort B
Patients with advanced/metastatic, histologically confirmed, grade 1/2 (G1/G2) of 2010 WHO (World Health Organization) classification neuroendocrine tumors of gastrointestinal tract after progression to somatostatin analogues Treatment: Dosing schedule of 24 mg once a day of Lenvatinib (two 10-mg capsules + one 4-mg capsule)
Group Type
EXPERIMENTAL
Lenvatinib
Intervention Type
DRUG
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lenvatinib
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
LENVIMA™
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Subjects must meet all of the following criteria to be included in this study:
1. Subjects must have histologically confirmed diagnosis of one of the following advanced/metastatic neuroendocrine tumor types:
1. WHO Classification G1/G2 (Ki67\<20% and mitotic count ≤20 mitoses x 10 HPF) pancreatic neuroendocrine tumor
2. WHO Classification G1/G2 (Ki67\<20% and mitotic count ≤20 mitoses x 10 HPF) gastrointestinal neuroendocrine tumor (including stomach, small intestine and colorectal origins).
2. Subjects must have evidence of measurable disease meeting the following criteria:
1. At least 1 lesion of ≥ 1.0 cm in the longest diameter for a non-lymph node, or ≥ 1.5 cm in the short-axis diameter for a lymph node, which is serially measurable according to RECIST 1.1 (Appendix I) using computerized tomography/magnetic resonance imaging (CT/MRI). If there is only one target lesion and it is a non-lymph node, it should have a longest diameter of ≥ 1.5 cm.
2. Lesions that have had external beam radiotherapy (EBRT) or loco-regional therapies such as radiofrequency (RF) ablation or liver embolization must show evidence of progressive disease based on RECIST 1.1 to be deemed a target lesion.
3. Subjects must show evidence of disease progression by radiologic image techniques within 12 months (an additional month will be allowed to accommodate actual dates of performance of scans, i.e., within ≤ 13 months) prior to signing informed consent, according to RECIST 1.1 (Appendix I)
4. Subjects must meet the following inclusion criterion regarding primary tumor site:
1. Pancreatic origin: progression after a previous targeted agent (including mTOR inhibitors, such as everolimus or antiangiogenic therapies, such as sunitinib, sorafenib, axitinib, bevacizumab within others). Combination therapies in the same treatment line (such as sorafenib plus bevacizumab, chemotherapy plus antiangiogenic drugs) are considered one treatment line and are allowed to be included in the study. Patients must be treated with only one previous line of targeted agent(s)-based therapy.
Previous therapy with somatostatin analogues and/or interferon is allowed and is not considered as a previous targeted agent therapy.
2. Gastrointestinal origin: progression after therapy with antitumoral doses of somatostatin analogs (octreotide LAR 30 mg every 28 days or Lanreotide 120 mg every 28 days) and/or interferon treatment.
5. Only for patients with pancreatic origin neuroendocrine tumors, one previous line with chemotherapy is allowed.
6. Concomitant somatostatin analogues are allowed in both cohorts during the study.
7. Patients with known brain metastases who have completed whole brain radiotherapy, stereotactic radiosurgery or complete surgical resection, will be eligible if they have remained clinically stable, asymptomatic and off of steroids for at least one month.
8. All prior chemotherapy or radiation-related toxicities must have resolved to \< Grade 2 (following CTCAE V 4.03 grade levels), except alopecia and infertility.
9. Subjects must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 - 1 (Appendix II).
10. Previous liver locoregional therapies, such as (chemo) embolization, radiofrequency or liver-directed (radio) embolization, or systemic peptide-receptor radionucleotide therapy are allowed if the procedure was performed at least 6 months previous the informed consent form signature.
11. Adequately controlled blood pressure with or without antihypertensive medications, defined as BP \< 150/90 mmHg at screening and no change in antihypertensive medications within 1 week prior to the Screening Visit.
12. Adequate renal function defined as calculated creatinine clearance ≥ 30 mL/min per the Cockcroft and Gault formula (Appendix III).
13. Adequate bone marrow function, defined as:
1. Absolute neutrophil count (ANC) ≥ 1500/mm3 (≥ 1.5 ×103/μL).
2. Platelets ≥ 100,000/mm3 (≥ 100 × 109/L).
3. Hemoglobin ≥ 9.0 g/dL.
14. Adequate blood coagulation function as evidenced by an International Normalized Ratio (INR) ≤ 1.5. Prophylactic low molecular weight heparin therapy is allowed.
15. Adequate liver function:
1. Bilirubin ≤ 1.5 × the upper limit of normal (ULN) except for unconjugated hyperbilirubinemia or Gilbert's syndrome.
2. Alkaline phosphatase, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) ≤ 3 × the ULN (≤ 5 × ULN if subject has liver metastases).
16. Males or females age ≥ 18 years at the time of informed consent.
17. All females must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of beta human chorionic gonadotropin (β-hCG) at the baseline visit (and/or within 72h prior to the first dose of study drug).
Females of childbearing potential must agree to use a highly effective method of contraception (e.g., total sexual abstinence\*, an intrauterine device, a double-barrier method such as condom + spermicide or condom + diaphragm with spermicide or have a vasectomized partner with confirmed azoospermia\*) throughout the entire study period and for 30 days after study drug administration. The only subjects who will be exempt from this requirement are postmenopausal women (defined as women who have been amenorrheic for at least 12 consecutive months, in the appropriate age group, without other known or suspected primary cause) or subjects who have been sterilized surgically or who are otherwise proven sterile (i.e., bilateral tubal ligation with surgery at least 1 month prior to dosing, hysterectomy, or bilateral oophorectomy with surgery at least 1 month prior to dosing).
The women using oral hormonal contraceptives should add an additional barrier method as there is unknown whether lenvatinib may reduce the effectiveness of the hormonal contraceptives. All women who are of reproductive potential and who are using hormonal contraceptives must have been on a stable dose of the same hormonal contraceptive product for at least 4 weeks prior to dosing and must continue to use the same contraceptive during the study and for 30 days after study drug discontinuation.
\*\* Sexual abstinence will be acceptable only when this is in line with the preferred and usual lifestyle of the subject.
18. Male subjects who are partners of women of childbearing potential must use or their partners must use a highly effective method of contraception (e.g., condom + spermicide, condom + diaphragm with spermicide, IUD) beginning at least 1 menstrual cycle prior to starting study drug(s), throughout the entire study period, and for 30 days after the last dose of study drug, unless they are sexually abstinent or have undergone a successful vasectomy. Those with partners using hormonal contraceptives must also be using an additional approved method of contraception, as described previously.
19. Voluntary provision of written informed consent and the willingness and ability to comply with all aspects of the protocol.
1. Subjects must have histologically confirmed diagnosis of one of the following advanced/metastatic neuroendocrine tumor types:
1. WHO Classification G1/G2 (Ki67\<20% and mitotic count ≤20 mitoses x 10 HPF) pancreatic neuroendocrine tumor
2. WHO Classification G1/G2 (Ki67\<20% and mitotic count ≤20 mitoses x 10 HPF) gastrointestinal neuroendocrine tumor (including stomach, small intestine and colorectal origins).
2. Subjects must have evidence of measurable disease meeting the following criteria:
1. At least 1 lesion of ≥ 1.0 cm in the longest diameter for a non-lymph node, or ≥ 1.5 cm in the short-axis diameter for a lymph node, which is serially measurable according to RECIST 1.1 (Appendix I) using computerized tomography/magnetic resonance imaging (CT/MRI). If there is only one target lesion and it is a non-lymph node, it should have a longest diameter of ≥ 1.5 cm.
2. Lesions that have had external beam radiotherapy (EBRT) or loco-regional therapies such as radiofrequency (RF) ablation or liver embolization must show evidence of progressive disease based on RECIST 1.1 to be deemed a target lesion.
3. Subjects must show evidence of disease progression by radiologic image techniques within 12 months (an additional month will be allowed to accommodate actual dates of performance of scans, i.e., within ≤ 13 months) prior to signing informed consent, according to RECIST 1.1 (Appendix I)
4. Subjects must meet the following inclusion criterion regarding primary tumor site:
1. Pancreatic origin: progression after a previous targeted agent (including mTOR inhibitors, such as everolimus or antiangiogenic therapies, such as sunitinib, sorafenib, axitinib, bevacizumab within others). Combination therapies in the same treatment line (such as sorafenib plus bevacizumab, chemotherapy plus antiangiogenic drugs) are considered one treatment line and are allowed to be included in the study. Patients must be treated with only one previous line of targeted agent(s)-based therapy.
Previous therapy with somatostatin analogues and/or interferon is allowed and is not considered as a previous targeted agent therapy.
2. Gastrointestinal origin: progression after therapy with antitumoral doses of somatostatin analogs (octreotide LAR 30 mg every 28 days or Lanreotide 120 mg every 28 days) and/or interferon treatment.
5. Only for patients with pancreatic origin neuroendocrine tumors, one previous line with chemotherapy is allowed.
6. Concomitant somatostatin analogues are allowed in both cohorts during the study.
7. Patients with known brain metastases who have completed whole brain radiotherapy, stereotactic radiosurgery or complete surgical resection, will be eligible if they have remained clinically stable, asymptomatic and off of steroids for at least one month.
8. All prior chemotherapy or radiation-related toxicities must have resolved to \< Grade 2 (following CTCAE V 4.03 grade levels), except alopecia and infertility.
9. Subjects must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 - 1 (Appendix II).
10. Previous liver locoregional therapies, such as (chemo) embolization, radiofrequency or liver-directed (radio) embolization, or systemic peptide-receptor radionucleotide therapy are allowed if the procedure was performed at least 6 months previous the informed consent form signature.
11. Adequately controlled blood pressure with or without antihypertensive medications, defined as BP \< 150/90 mmHg at screening and no change in antihypertensive medications within 1 week prior to the Screening Visit.
12. Adequate renal function defined as calculated creatinine clearance ≥ 30 mL/min per the Cockcroft and Gault formula (Appendix III).
13. Adequate bone marrow function, defined as:
1. Absolute neutrophil count (ANC) ≥ 1500/mm3 (≥ 1.5 ×103/μL).
2. Platelets ≥ 100,000/mm3 (≥ 100 × 109/L).
3. Hemoglobin ≥ 9.0 g/dL.
14. Adequate blood coagulation function as evidenced by an International Normalized Ratio (INR) ≤ 1.5. Prophylactic low molecular weight heparin therapy is allowed.
15. Adequate liver function:
1. Bilirubin ≤ 1.5 × the upper limit of normal (ULN) except for unconjugated hyperbilirubinemia or Gilbert's syndrome.
2. Alkaline phosphatase, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) ≤ 3 × the ULN (≤ 5 × ULN if subject has liver metastases).
16. Males or females age ≥ 18 years at the time of informed consent.
17. All females must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of beta human chorionic gonadotropin (β-hCG) at the baseline visit (and/or within 72h prior to the first dose of study drug).
Females of childbearing potential must agree to use a highly effective method of contraception (e.g., total sexual abstinence\*, an intrauterine device, a double-barrier method such as condom + spermicide or condom + diaphragm with spermicide or have a vasectomized partner with confirmed azoospermia\*) throughout the entire study period and for 30 days after study drug administration. The only subjects who will be exempt from this requirement are postmenopausal women (defined as women who have been amenorrheic for at least 12 consecutive months, in the appropriate age group, without other known or suspected primary cause) or subjects who have been sterilized surgically or who are otherwise proven sterile (i.e., bilateral tubal ligation with surgery at least 1 month prior to dosing, hysterectomy, or bilateral oophorectomy with surgery at least 1 month prior to dosing).
The women using oral hormonal contraceptives should add an additional barrier method as there is unknown whether lenvatinib may reduce the effectiveness of the hormonal contraceptives. All women who are of reproductive potential and who are using hormonal contraceptives must have been on a stable dose of the same hormonal contraceptive product for at least 4 weeks prior to dosing and must continue to use the same contraceptive during the study and for 30 days after study drug discontinuation.
\*\* Sexual abstinence will be acceptable only when this is in line with the preferred and usual lifestyle of the subject.
18. Male subjects who are partners of women of childbearing potential must use or their partners must use a highly effective method of contraception (e.g., condom + spermicide, condom + diaphragm with spermicide, IUD) beginning at least 1 menstrual cycle prior to starting study drug(s), throughout the entire study period, and for 30 days after the last dose of study drug, unless they are sexually abstinent or have undergone a successful vasectomy. Those with partners using hormonal contraceptives must also be using an additional approved method of contraception, as described previously.
19. Voluntary provision of written informed consent and the willingness and ability to comply with all aspects of the protocol.
Exclusion Criteria
1. WHO Classification G3 neuroendocrine tumors of the pancreas and gastrointestinal tract.
2. Two or more prior lines of targeted agents-based therapy in pancreatic origin and any previous line of targeted therapy for gastrointestinal origin or any ongoing antiproliferative treatment for advanced/metastatic neuroendocrine tumors, with the exception of somatostatin analogues therapy.
3. More than one previous line of chemotherapy in pancreatic neuroendocrine tumors.
4. Previous chemotherapy in gastrointestinal neuroendocrine tumors.
5. Prior treatment with lenvatinib.
6. Subjects who have received any anti-cancer treatment within 21 days or any investigational agent within 30 days prior to the first dose of study drug and should have recovered from any toxicity related to previous anti-cancer treatment. This does not apply to the use of somatostatin analogues for symptomatic therapy.
7. Major surgery within 3 weeks prior to the first dose of study drug.
8. Subjects having \> 1+ proteinuria on urine dipstick testing will undergo 24h urine collection for quantitative assessment of proteinuria. Subjects with urine protein ≥ 1 g/24h will be ineligible.
9. Gastrointestinal malabsorption, or any other condition in the opinion of the investigator that might affect the absorption of lenvatinib.
10. Significant cardiovascular impairment: history of congestive heart failure greater than New York Heart Association (NYHA) Class II, unstable angina; myocardial infarction or stroke within 6 months prior to the first dose of study drug, or cardiac arrhythmia requiring medical treatment. The left ventricular ejection fraction in the echocardiogram must be of at least 50%.
11. Prolongation of QTcF interval to \> 480 msec.
12. Bleeding or thrombotic disorders or use of anticoagulants, such as warfarin, or similar agents requiring therapeutic international normalized ration (INR) monitoring. Treatment with low molecular weight heparin (LMWH) is allowed.
13. Active hemoptysis (bright red blood of at least 0.5 teaspoon) within 3 weeks prior to the first dose of study drug.
14. Active infection (any infection requiring treatment).
15. Active malignancy within the past 5 years (except for definitely treated melanoma in-situ, basal or squamous cell carcinoma of the skin, or carcinoma in-situ of the cervix).
16. Known intolerance or hypersensitivity to the active substance (or any of the excipients).
17. Any medical or other condition which, in the opinion of the investigator, would preclude participation in a clinical trial.
18. Females who are pregnant or breastfeeding.
19. Documented active alcohol or drug abuse.
20. Patients with a prior history of non-compliance with medical regimens.
2. Two or more prior lines of targeted agents-based therapy in pancreatic origin and any previous line of targeted therapy for gastrointestinal origin or any ongoing antiproliferative treatment for advanced/metastatic neuroendocrine tumors, with the exception of somatostatin analogues therapy.
3. More than one previous line of chemotherapy in pancreatic neuroendocrine tumors.
4. Previous chemotherapy in gastrointestinal neuroendocrine tumors.
5. Prior treatment with lenvatinib.
6. Subjects who have received any anti-cancer treatment within 21 days or any investigational agent within 30 days prior to the first dose of study drug and should have recovered from any toxicity related to previous anti-cancer treatment. This does not apply to the use of somatostatin analogues for symptomatic therapy.
7. Major surgery within 3 weeks prior to the first dose of study drug.
8. Subjects having \> 1+ proteinuria on urine dipstick testing will undergo 24h urine collection for quantitative assessment of proteinuria. Subjects with urine protein ≥ 1 g/24h will be ineligible.
9. Gastrointestinal malabsorption, or any other condition in the opinion of the investigator that might affect the absorption of lenvatinib.
10. Significant cardiovascular impairment: history of congestive heart failure greater than New York Heart Association (NYHA) Class II, unstable angina; myocardial infarction or stroke within 6 months prior to the first dose of study drug, or cardiac arrhythmia requiring medical treatment. The left ventricular ejection fraction in the echocardiogram must be of at least 50%.
11. Prolongation of QTcF interval to \> 480 msec.
12. Bleeding or thrombotic disorders or use of anticoagulants, such as warfarin, or similar agents requiring therapeutic international normalized ration (INR) monitoring. Treatment with low molecular weight heparin (LMWH) is allowed.
13. Active hemoptysis (bright red blood of at least 0.5 teaspoon) within 3 weeks prior to the first dose of study drug.
14. Active infection (any infection requiring treatment).
15. Active malignancy within the past 5 years (except for definitely treated melanoma in-situ, basal or squamous cell carcinoma of the skin, or carcinoma in-situ of the cervix).
16. Known intolerance or hypersensitivity to the active substance (or any of the excipients).
17. Any medical or other condition which, in the opinion of the investigator, would preclude participation in a clinical trial.
18. Females who are pregnant or breastfeeding.
19. Documented active alcohol or drug abuse.
20. Patients with a prior history of non-compliance with medical regimens.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eisai Limited
INDUSTRY
Sponsor Role
collaborator
Experior S.L.
UNKNOWN
Sponsor Role
collaborator
Grupo Espanol de Tumores Neuroendocrinos
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Universitätsklinik für Innere Medizin
Graz, , Austria
Site Status
Medizinische Universität Wien
Vienna, , Austria
Site Status
Spedali Civili di Brescia
Brescia, , Italy
Site Status
Instituto Oncologico Mediterraneo
Catania, , Italy
Site Status
Azienda Ospedaliero Universitaria Careggi - SC di Oncologia
Florence, , Italy
Site Status
IRST of Meldola
Meldola, , Italy
Site Status
Istituto Europeo di Oncologia - Unità di Oncologia Medica Gastrointestinale e Tumori Neuroendocrini
Milan, , Italy
Site Status
AOU Policlinico di Modena - DH Oncologico
Modena, , Italy
Site Status
IRCCS Napoli
Napoli, , Italy
Site Status
Hospital Universatorio de Verona
Verona, , Italy
Site Status
Hospital Virgen de la Victoria
Málaga, Andalusia, Spain
Site Status
Hospital de Donostia
Donostia / San Sebastian, Basque Country, Spain
Site Status
Hospital Marqués de Valdecilla
Santander, Cantabria, Spain
Site Status
Hospital Central de Asturias
Oviedo, Principality of Asturias, Spain
Site Status
Hospital Universitario Vall Hebrón
Barcelona, , Spain
Site Status
ICO Hospitalet
L'Hospitalet de Llobregat, , Spain
Site Status
Hospital Universitario Ramón y Cajal
Madrid, , Spain
Site Status
Hospital Universitario 12 de Octubre
Madrid, , Spain
Site Status
Hospital Universitario la Paz
Madrid, , Spain
Site Status
Hospital Miguel Servet
Zaragoza, , Spain
Site Status
Beatson Oncology Centre Gartnavel General Hospital
Glasgow, , United Kingdom
Site Status
Christie Hospital, Manchester
Manchester, , United Kingdom
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Austria
Italy
Spain
United Kingdom
References
Explore related publications, articles, or registry entries linked to this study.
Ligero M, Hernando J, Delgado E, Garcia-Ruiz A, Merino-Casabiel X, Ibrahim T, Fazio N, Lopez C, Teule A, Valle JW, Tafuto S, Custodio A, Reed N, Raderer M, Grande E, Garcia-Carbonero R, Jimenez-Fonseca P, Garcia-Alvarez A, Escobar M, Casanovas O, Capdevila J, Perez-Lopez R. Radiomics and outcome prediction to antiangiogenic treatment in advanced gastroenteropancreatic neuroendocrine tumours: findings from the phase II TALENT trial. BJC Rep. 2023 Aug 2;1(1):9. doi: 10.1038/s44276-023-00010-0.
Reference Type
DERIVED
Capdevila J, Fazio N, Lopez C, Teule A, Valle JW, Tafuto S, Custodio A, Reed N, Raderer M, Grande E, Garcia-Carbonero R, Jimenez-Fonseca P, Hernando J, Bongiovanni A, Spada F, Alonso V, Antonuzzo L, Spallanzani A, Berruti A, La Casta A, Sevilla I, Kump P, Giuffrida D, Merino X, Trejo L, Gajate P, Matos I, Lamarca A, Ibrahim T. Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509). J Clin Oncol. 2021 Jul 10;39(20):2304-2312. doi: 10.1200/JCO.20.03368. Epub 2021 May 4.
Reference Type
DERIVED
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2015-001467-39
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
GETNE1509
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
NCT00075439
COMPLETED
PHASE2
Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC)
NCT03240393
WITHDRAWN
PHASE2
A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (TRIGGER)
NCT01378962
COMPLETED
PHASE2
Investigation of GSK2879552 in Subjects With Relapsed/Refractory Small Cell Lung Carcinoma
NCT02034123
TERMINATED
PHASE1
Real-world Study of Taletrectinib in Advanced ROS1+ NSCLC Following Entrectinib Progression
NCT07199010
NOT_YET_RECRUITING
A Study of Tarceva (Erlotinib) Monotherapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT01996332
COMPLETED
PHASE2
Erlotinib 100mg qd Versus Gefitinib 250mg qd for EGFR Mutant Nsclc
NCT01955421
UNKNOWN
PHASE2
A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases
NCT04603807
RECRUITING
PHASE3
A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations
NCT01260181
COMPLETED
PHASE2
Osimertinib (AZD9291) in First-line Locally Advanced or Metastatic NSCLC Patients With EGFR and EGFR T790M
NCT02841579
COMPLETED
PHASE2
A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients
NCT05078931
ACTIVE_NOT_RECRUITING
PHASE2
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
NCT06562192
RECRUITING
PHASE1
Irinotecan Liposome Combined with S-1 in PD-1/L1 Inhibitor Refractory Recurrent or Metastatic NPC
NCT06657690
RECRUITING
PHASE2
Best EGFR-TKI Sequence in NSCLC Harboring EGFR Mutations
NCT04811001
UNKNOWN
PHASE2
AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
NCT02296125
COMPLETED
PHASE3
Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations.
NCT02097810
COMPLETED
PHASE1
Evaluate Erlotinib Efficacy and Safety as the 2nd/3rd Treatment in NSCLC With EGFR M(-) and C-met(-)
NCT02006043
UNKNOWN
PHASE2
An Observational Study of Tarceva (Erlotinib) in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer With Wild-Type Epidermal Growth Factor Receptor (EGFR) Gene (WILT)
NCT01512420
COMPLETED
A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations
NCT01609543
COMPLETED
PHASE4
Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLC
NCT02474355
COMPLETED
PHASE3
A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer (NSCLC) Which Has Spread Out.
NCT06678555
RECRUITING
Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)
NCT02414139
COMPLETED
PHASE2
Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT00080340
COMPLETED
PHASE3
Efficacy & Safety Study of Lorlatinib in ALK/ROS1 Metastatic NSCLC Patients With Compassionate Use Treatment
NCT05167500
COMPLETED
Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Prospective Study
NCT04401059
RECRUITING
PHASE4